Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 25:27:100486.
doi: 10.1016/j.ijcha.2020.100486. eCollection 2020 Apr.

Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry

Michele Correale  1 , Adriana Mallardi  2 , Pietro Mazzeo  2 , Lucia Tricarico  2 , Claudia Diella  2 , Valentina Romano  2 , Armando Ferraretti  3 , Alessandra Leopizzi  2 , Giuseppina Merolla  1 , Matteo Di Biase  2 , Natale Daniele Brunetti  2
Affiliations

Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry

Michele Correale et al. Int J Cardiol Heart Vasc. .

Abstract

Background: Previous studies and case-series showed improvement in left ventricular (LV) function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We therefore aimed to evaluate whether also right ventricular (RV) function may improve after sacubitril/valsartan therapy.

Methods: Sixty consecutive patients with chronic heart failure and NYHA class II-III were followed up for 12 months after therapy with sacubitril/valsartan. Left and (RV) function was assessed at baseline and after 12 months of therapy.

Results: At 12-month control, therapy with sacubitril/valsartan was associated with a significant improvement in a series of echo parameters: LVEF (p < 0.05), LV end-systolic volume (p < 0.01), left atrium area (p < 0.05).Right ventricular echo parameters were also improved after sacubitril/valsartan therapy: PAsP (31.0 ± 12.8 vs 34.7 ± 12.5 mmHg, p < 0.05), TAPSE (17.8 ± 3.9 vs 16.5 ± 4.0 mm, p < 0.001); mean PAsP reduction was 3.7 ± 11.4 mmHg (-6.3 ± 37.7%), mean TAPSE increase 1.3 ± 2.5 mm (+9.5 ± 15.7%).Indexed (%) improvement in PAsP (r 0.33, p < 0.01) and TAPSE (r -0.42, p < 0.01) values were proportional to baseline levels. Improvement in PAsP and TAPSE were independent of left ventricular improvements except for PAsP and end-systolic volumes (r 0.44, p < 0.01).

Conclusions: In a real world scenario, sacubitril/valsartan was associated with an improved RV function.

Keywords: ARNI; Chronic heart failure; Neprilysin inhibitors; Right ventricular function; Sacubitril valsartan.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Systolic pulmonary arterial pression (p < 0.05) and TAPSE (p < 0.001) improvement after 12-month therapy with sacubitril/valsartan.
Fig. 2
Fig. 2
Linear correlation between baseline sPAP (r 0.33, p < 0.01) and TAPSE (r −0.42, p < 0.01) levels and indexed (%) changes after 12-month therapy with sacubitril/valsartan.
See this image and copyright information in PMC

References

    1. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K. Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014;371:993–1004. - PubMed
    1. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J., Falk V., Gonzalez-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M., Ruilope L.M., Ruschitzka F., Rutten F.H., Van der Meer P. 2016 ESC Guidelines for the diagnosis 535 and treatment of acute and chronic heart failure: The Task Force 536 for the diagnosis and treatment of acute and chronic heart failure 537 of the European Society of Cardiology (ESC). Developed with the 538 special contribution of the Heart Failure Association (HFA) of the 539 ESC. Eur. J. Heart Fail. 2016;18:891–975. - PubMed
    1. Valle R., Aspromonte N. Sacubitril/Valsartan in Clinical Practice: The Italian Experience. Cardiology. 2017;138(Suppl 1):1–2. - PubMed
    1. Vincenzi A., Cesana F., Cirò A., Garatti L., Achilli F. Sacubitril/Valsartan in “Field Practice” Patients with Advanced Heart Failure: A Monocentric Italian Experience. Cardiology. 2017;138:13–16. - PubMed
    1. Martens P., Beliën H., Dupont M., Vandervoort P., Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc. Ther. 2018;36 - PubMed

LinkOut - more resources